Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Paul K. Audhya"'
Autor:
Edward P. Feener, Rebecca L. Davie, Nivetha Murugesan, Stephen J. Pethen, Sally L. Hampton, Michael D. Smith, Paul K. Audhya, Chris M. Yea
Publikováno v:
Drugs and Drug Candidates, Vol 3, Iss 2, Pp 328-341 (2024)
Sebetralstat is a novel, potent, and selective oral plasma kallikrein inhibitor drug candidate in clinical development for the on-demand treatment of hereditary angioedema (HAE). Upon binding, sebetralstat induces a conformational change in the activ
Externí odkaz:
https://doaj.org/article/c898ea85087542009c61e6fcd2741b8b
Autor:
Danny M. Cohn, Emel Aygören‐Pürsün, Jonathan A. Bernstein, Henriette Farkas, William R. Lumry, Marcus Maurer, Andrea Zanichelli, Matthew Iverson, James Hao, Michael D. Smith, Christopher M. Yea, Paul K. Audhya, Marc A. Riedl
Publikováno v:
Clinical and Translational Allergy, Vol 13, Iss 9, Pp n/a-n/a (2023)
Abstract Background Hereditary angioedema (HAE) with C1‐inhibitor deficiency (HAE‐C1‐INH) is characterized by recurrent, debilitating episodes of swelling. Sebetralstat, an investigational oral plasma kallikrein inhibitor, demonstrated promisin
Externí odkaz:
https://doaj.org/article/fa5357d5066e444bb5ad301768e9507f
Autor:
Emel Aygören-Pürsün, Andrea Zanichelli, Danny M Cohn, Mauro Cancian, Roman Hakl, Tamar Kinaciyan, Markus Magerl, Inmaculada Martinez-Saguer, Marcin Stobiecki, Henriette Farkas, Sorena Kiani-Alikhan, Vesna Grivcheva-Panovska, Jonathan A Bernstein, H Henry Li, Hilary J Longhurst, Paul K Audhya, Michael D Smith, Christopher M Yea, Andreas Maetzel, Daniel K Lee, Edward P Feener, Richard Gower, William R Lumry, Aleena Banerji, Marc A Riedl, Marcus Maurer
Publikováno v:
The Lancet, 401(10375), 458-469. Elsevier Limited
Background: Guidelines recommend effective on-demand therapy for all individuals with hereditary angioedema. We aimed to assess the novel oral plasma kallikrein inhibitor, sebetralstat, which is in development, for on-demand treatment of hereditary a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecd222b086018bb478d12029297cd21f
https://ruj.uj.edu.pl/xmlui/handle/item/309592
https://ruj.uj.edu.pl/xmlui/handle/item/309592
Publikováno v:
The Journal of Allergy and Clinical Immunology: In Practice.
Autor:
C. Kors van der Ent, Renske van der Meer, Sylvia F. Boj, Robert G.J. Vries, Harry G.M. Heijerman, Peter van Mourik, Paul K. Audhya, Jamie R Doyle, Jeffrey M. Beekman, Zheng Jason Yuan, N. Kinnman, Gitte Berkers
Publikováno v:
Journal of Cystic Fibrosis. 20:761-767
Background Previous in vitro organoid data showed A455E–CFTR, a rare CFTR mutation with 4.1% prevalence in the Netherlands, responds to lumacaftor/ivacaftor (LUM/IVA). We explored LUM/IVA's clinical efficacy in people with CF and ≥1 A455E–CFTR
Autor:
Neil Ahluwalia, Bote G. Bruinsma, Carsten Schwarz, Margaret E. Duncan, Rainald Fischer, Ralph Epaud, Paul K. Audhya, X You, Ross C. Klingsberg, Steven M. Rowe, Thomas J. Ferro, Sivagurunathan Sutharsan
Publikováno v:
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society. 20(2)
Background: Increased rates of respiratory adverse events have been observed in people ≥12 years of age with cystic fibrosis homozygous for the Phe508del-CFTR mutation treated with lumacaftor/ivacaftor, particularly in those with percent predicted
Autor:
Steven M. Rowe, R Epaud, T Ferro, X You, Ross C. Klingsberg, L Wang, S Sutharsan, Paul K. Audhya, Carsten Schwarz, Rainald Fischer
Publikováno v:
60. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e. V..